Bouhaha R.,Laboratory of Genetics |
Baroudi T.,Laboratory of Genetics |
Ennafaa H.,Laboratory of Genetics |
Vaillant E.,French National Center for Scientific Research |
And 7 more authors.
Objectives: We investigated two genetic markers in pro inflammatory molecules: TNFα -308G/A and IL6 -174G/C in order to assess their effect on type 2 diabetes (T2D) and obesity in the Tunisian population. Design and methods: The study sample includes 228 patients with T2D and 300 healthy controls. Genotyping of IL6 -174G/C (rs1800795) was performed using Automated Dye Terminator Sequencing and of TNFα -308G/A (rs1800629) using the LightTyper technology. Results: SNPs IL6 -174G/C and TNFα -308G/A are associated neither with T2D (p=0.89, p=0.34 respectively) nor with risk for overweight (p=0.86, p=0.12 respectively) in Tunisian population. Bonferroni correction showed that the founded association of IL6 -174G/C SNP with T2D susceptibility restricted to overweight patients (pnominal=0.03, pcorrected=0.0033) is likely to be a random result. Conclusion: SNPs IL6 -174G/C and TNFα -308G/A are not major contributors to T2D or obesity risk in our Tunisian population. © 2010 The Canadian Society of Clinical Chemists. Source
Ben Jemaa A.,University of Carthage |
Bouraoui Y.,University of Carthage |
Sallami S.,Hospital of La Rabta |
Banasr A.,Hospital of Charles Nicolle |
And 2 more authors.
Aim: The relevance of prostate specific antigen (PSA)-prostate specific membrane antigen (PSMA) profiles in pathologic prostate (hyperplasia and cancer) has not been fully understood. The aim of this study is to investigate the impact of PSA-PSMA profiles on sera PSA levels and angiogenic activity in benign prostate hyperplasia (BPH) and prostate carcinoma (PC). Patients and methods: The study has been carried out in 6 normal prostate (NP), 29BPH and 33PC with dominant Gleason grade. > 8. Immunohistochemical analysis has been performed. Monoclonal antibodies 3E6 and ER-PR8 have been used to assess PSMA and PSA expression respectively. The evaluation of angiogenesis has been made by CD34 immune marker. Serum levels of PSA have been assayed by Immulite autoanalyser. Results: The study of each protein separately among sera PSA levels showed that PSMA expression and angiogenic activity have the highest intensity in PC patients with serum PSA levels > 20. ng/mL. Nevertheless, the lowest tissue PSA expression was found in PC patients with this latter sera PSA group. The most relevant results showed that in PC patients (PSA+, PSMA+) and (PSA-, PSMA+) profile were found to be inversely related to sera PSA levels. In PC patients, a high immunoexpression of (PSA+, PSMA+) profile has detected in the sera PSA group > 20. ng/mL; whereas a high immunoexpression of (PSA-, PSMA+) profile was detected in the sera PSA group between 0 and 4. ng/mL. The highest angiogenic activity was found in PC patients with (PSA+, PSMA+) profile. Conclusions: Our findings clearly have supported the feasibility of PSA-PSMA profiles to improve in vivo diagnostic and therapeutic approaches in prostate cancer patients. © 2014. Source
Bouhaha R.,Laboratory of Genetics |
Choquet H.,French National Center for Scientific Research |
Meyre D.,French National Center for Scientific Research |
Abid Kamoun H.,Hospital of Charles Nicolle |
And 8 more authors.
The transcription factor 7-like 2 (TCF7L2) rs7903146 T allele was associated with type 2 diabetes (T2D) in most populations worldwide. In individuals of European descent, the association with T2D was recently found to be modulated by obesity status. However, further studies are necessary to clarify if whether interaction exists among subjects of non-European descent. In the present study, we analyzed the association of rs7903146 with T2D in 90 nonobese (Body Mass Index [BMI] <25kg/m2), 171 overweight (25≤BMI<30kg/m2) et 98 obese (BMI≥30kg/m2) individuals from Tunisia. The T allele was nominally associated with T2D in nonobese subjects (Odds Ratio [OR]=3.24 [1.10-9.53], P=0.021) whereas no effect was detected in overweight (P=0.3) and obese (P=0.22) individuals. Consequently, the same risk allele decreased susceptibility to obesity in T2D subjects (OR=0.47 [0.23-0.94], P=0.029) but not in normoglycemic controls (P=0.44). When analyzed all together, no allelic association was observed with T2D (P=0.20) whereas an artefactual association with decreased obesity (0.59 [0.38-0.90], P=0.013) was detected. As in Europeans, TCF7L2 is therefore not a risk factor for obesity in Tunisians, but its effect on T2D risk is modulated by obesity. In conclusion, the TCF7L2 rs7903146 T allele is nominally associated with T2D susceptibility in nonobese individuals from Tunisia. © 2009 Elsevier Masson SAS. Source
Berhouma R.,Tunis el Manar University |
Kouidhi S.,Tunis el Manar University |
Ammar M.,Tunis el Manar University |
Abid H.,Hospital of Charles Nicolle |
And 2 more authors.
Our study aimed to analyze whether the expression of PPARγ mRNA in subcutaneous adipocyte tissue correlates with Pro12Ala PPARγ2 polymorphism in the obesity context. We found that mRNA expression of PPARγ in subcutaneous adipose tissue was greater in obese subjects (P < 0.05) than in the nonobese control group. Concurrently, genotyping of the Pro12Ala polymorphism showed that obese subjects possess a significantly higher frequency of the Pro/Pro genotype than nonobese controls (90.5 vs 79.5%; P = 0.03), suggesting that this genotype is involved in an increased risk of obesity in the Tunisian population. Taken together, our results demonstrate that the Pro12 allele is accompanied by an overexpression of PPARγ mRNA in subcutaneous adipocyte tissue, suggesting that the PPARγ Pro12Ala variant may contribute to the observed variability in PPARγ mRNA expression and consequently in body mass index and insulin sensitivity in the general population. © 2013 Springer Science+Business Media New York. Source